<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7910918</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5452</journal-id>
<journal-id journal-id-type="nlm-ta">J Inherit Metab Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Inherit. Metab. Dis.</journal-id>
<journal-title-group>
<journal-title>Journal of inherited metabolic disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0141-8955</issn>
<issn pub-type="epub">1573-2665</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30740726</article-id>
<article-id pub-id-type="pmc">6279618</article-id>
<article-id pub-id-type="doi">10.1002/jimd.12035</article-id>
<article-id pub-id-type="manuscript">NIHMS972743</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Characteristics and outcomes of patients with formiminoglutamic aciduria detected through newborn screening</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ahrens-Nicklas</surname>
<given-names>Rebecca C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
<xref ref-type="author-notes" rid="FN1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ganetzky</surname>
<given-names>Rebecca D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rush</surname>
<given-names>Peggy W.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conway</surname>
<given-names>Robert L.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ficicioglu</surname>
<given-names>Can</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Division of Human Genetics, The Children’s Hospital of Philadelphia</aff>
<aff id="A2">
<label>2</label>Division of Genetic, Genomic, and Metabolic Disorders, The Children’s Hospital of Michigan</aff>
<author-notes>
<corresp id="FN1"><label>#</label>Corresponding author: Rebecca Ahrens-Nicklas, Colket Translational Research Building, 3501 Civic Center Blvd, Floor 9, Philadelphia, PA19104</corresp>
<fn fn-type="equal" id="FN2">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p>
<bold>Conflicts of Interest:</bold>
</p>
<p><bold>RA:</bold> No conflicts of interest to disclose</p>
<p><bold>RG:</bold> Received a one-time consulting fee from Dudnyk Healthcare Marketing</p>
<p><bold>PR:</bold> No conflicts of interest to disclose</p>
<p><bold>RC:</bold> Site PI for industry-sponsored clinical trial (BioMarin Pharmaceutical Inc). Past site PI and <italic>ad hoc</italic> consultant for Horizon Therapeutics, Inc.</p>
<p><bold>CF:</bold> Provided consulting support to and received grant support and honoraria for speaking engagements from BioMarin Pharmaceutical Inc., Abbott Laboratories, Alexion Pharmaceuticals Inc., Shire, Pfizer, Swedish Orphan Biovitrum (Sobi), Sanofi-Genzyme, and Horizon Therapeutics, Inc.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2020</year>
</pub-date>
<volume>42</volume>
<issue>1</issue>
<fpage>140</fpage>
<lpage>146</lpage>
<!--elocation-id from pubmed: 10.1002/jimd.12035-->
<abstract>
<title>Summary</title>
<sec id="S1">
<title>Background</title>
<p id="P1">Glutamate formiminotransferase deficiency (FTCD deficiency) or formiminoglutamic aciduria is the second most common of the known inherited disorders of folate metabolism. Initial case reports suggested that patients may have severe intellectual disability and megaloblastic anemia. However, these cases were obtained from screening cohorts of patients with developmental delay. Subsequently, patients with milder clinical phenotypes have been reported. The full phenotypic spectrum of this disorder remains unknown.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">In many states, FTCD deficiency can be incidentally detected on tandem mass spectrometrybased newborn screening of dried blood spots. In this work, we report the outcomes of infants identified to have FTCD deficiency through newborn screening.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">During the study period, 18 patients were identified to have FTCD deficiency and were referred and evaluated at one of the two participating metabolic centers. The overall rate of FTCD deficiency detected through the New Jersey screening program over the study time period was 1:58,982. At a mean age of 56 months at last follow-up, 3/18 (16%) had developmental delays requiring individualized education plans; no patients had profound intellectual disability. 4/16 (25%) had mild self-limited anemia; no patients had profound anemia.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">These data suggest that the majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Glutamate formiminotransferase deficiency</kwd>
<kwd>formiminoglutamic aciduria</kwd>
<kwd>newborn screening</kwd>
<kwd>intellectual disability</kwd>
<kwd>anemia</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>